Results 111 to 120 of about 21,815 (182)
Targeting androgen receptor (AR) has shown great therapeutic potential in triple-negative breast cancer (TNBC), yet its efficacy remains unsatisfactory.
Fangyan Gao +9 more
doaj +1 more source
Purpose The real-world effectiveness and safety of abiraterone or enzalutamide in the Asian population with metastatic castration-resistant prostate cancer (mCRPC) remains unclear.
Wen-Kuan Huang +11 more
doaj +1 more source
Treatment with androgen-targeted therapies can induce upregulation of epithelial plasticity pathways. Epithelial plasticity is known to be important for metastatic dissemination and therapeutic resistance.
Armstrong, Andrew J +10 more
core +1 more source
Enzalutamide is a second-generation nonsteroidal antiandrogen clinically approved for the treatment of castration-resistant prostate cancer (CRPC), yet resistance to endocrine therapy has limited its success in this setting.
Pete E. Pascuzzi +7 more
core +1 more source
Enzalutamide inhibits PEX10 function and sensitizes prostate cancer cells to ROS activators
Sharply increased reactive oxygen species (ROS) are thought to induce oxidative stress, damage cell structure and cause cell death; however, its role in prostate cancer remains unclear.
Yuankang Feng +13 more
doaj +1 more source
157 Background: Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs progression-free and overall survival, but resistance and lethal disease eventually prevail ...
Mary-Ellen Taplin +12 more
core +1 more source
Molecular mechanisms of enzalutamide resistance in prostate cancer
An estimated 30,000 men in the United States will die of metastatic prostate cancer (PCa) each year due to the development of therapy resistance, most notably resistance to second-generation antiandrogen enzalutamide.
Raj, Ganesh V., Blatt, Eliot B.
core
227 Background: Cross-resistance between taxanes and androgen receptor axis targeted agents is a matter of debate in metastatic castration-resistant prostate cancer (mCRPC).
Frank Priou +18 more
core +1 more source
Background: Deep and rapid prostate-specific antigen (PSA) response is an important indicator to consider in treatment decision-making given its predictive value for long-term clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC ...
Mehmet A. Bilen +8 more
doaj +1 more source
MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer
Prostate cancer progression is driven by androgen receptor (AR) activity, which is a target for therapeutic approaches. Enzalutamide is an AR inhibitor that prolongs the survival of patients with advanced prostate cancer.
Wach, Sven +11 more
core +1 more source

